MER-101-03, a multicenter, phase II study to compare MER-101 20mg tablets to intravenous zoledronic acid 4mg in prostate cancer patients.

@article{McHugh2009MER10103AM,
  title={MER-101-03, a multicenter, phase II study to compare MER-101 20mg tablets to intravenous zoledronic acid 4mg in prostate cancer patients.},
  author={Catherine McHugh and Kieran Madigan and Angela Walsh and Jonathan Fox and Thomas Waymond Leonard and Jody Quint},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2009},
  volume={27 15\_suppl},
  pages={5161}
}
  • C. McHugh, K. Madigan, +3 authors J. Quint
  • Published 22 September 2016
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
5161 Background: The primary objective of this study is to examine the pharmacodynamic effects of two different regimens of zoledronic acid, Orazol 20 mg tablets versus Zometa 4mg IV infusion once-monthly therapy on biomarkers in male bisphosphonate-naïve hormone-refractory prostate cancer patients. METHODS The study is an open-label, multi-center phase II clinical trial to compare oral Orazol 20 mg tablets weekly, to infusions of intravenous Zometa 4mg monthly, in males with hormone… 
2 Citations
Safety and efficacy of sodium caprate in promoting oral drug absorption: from in vitro to the clinic.
TLDR
This work discusses how C(10)-based formulations are being tested for oral delivery of bisphosphonates using Gastro Intestinal Permeation Enhancement Technology, GIPET and in a related solid dose format for antisense oligonucleotides (ISIS Pharmaceuticals, USA).
Restoration of rat colonic epithelium after in situ intestinal instillation of the absorption promoter, sodium caprate.
TLDR
Design of optimized dosage forms containing C10 should corelease the payload and promoter close to the epithelium in high concentrations, because its remarkable capacity for epithelial repair may render this effect insignificant in vivo.